ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT

Euro / US Dollar

EURUSD
1.1393▲ 0.01%
As of 26/09/2026, 21:00:00

Overview

Open1.1391
Day Range1.13898 – 1.13935
52-Week Range1.13239 – 1.20656
Volume—
ADVERTISEMENT

Related News

AGF Management reports $74B AUM growth but misses Q3 EPS
ForexArticle

AGF Management reports $74B AUM growth but misses Q3 EPS

Toronto-based asset manager AGF saw year-over-year asset growth of 31% despite a 15% EPS shortfall and a 7% share price decline.

Sophie Laurent · 26 Sept 2026
STARLUX, American Airlines expand codeshare to 20 U.S. hubs
ForexArticle

STARLUX, American Airlines expand codeshare to 20 U.S. hubs

Taiwanese carrier STARLUX Airlines and American Airlines deepen transpacific connectivity with a codeshare expanding to 20 U.S. destinations, building on a 2025 interline agreement.

Sophie Laurent · 26 Sept 2026
China and US Agree to $30 Billion in Tariff Cuts, Extend Trade Peace
ForexArticle

China and US Agree to $30 Billion in Tariff Cuts, Extend Trade Peace

Washington and Beijing have settled on reciprocal tariff reductions worth $30 billion and launched an AI dialogue, extending a trade truce through November.

Sophie Laurent · 26 Sept 2026
US 10-Year Treasury Yield Hits 5.04% Amid Fed Rate Hike Concerns
ForexArticle

US 10-Year Treasury Yield Hits 5.04% Amid Fed Rate Hike Concerns

The yield on the benchmark 10-year U.S. Treasury note reached 5.04%, its highest level since July 2007, as markets priced in higher borrowing costs ahead of the Federal Reserve's policy decision on Wednesday.

Sophie Laurent · 26 Sept 2026
Japan Raises Rates, Joins U.S. in $34B Yen Intervention
ForexArticle

Japan Raises Rates, Joins U.S. in $34B Yen Intervention

Bank of Japan hikes policy rate while Tokyo and Washington coordinate a $34-36 billion FX operation to halt yen depreciation against the dollar.

Sophie Laurent · 26 Sept 2026
MediciNova Reports ALS Trial Completion, Eyes 2026 Topline Results
ForexArticle

MediciNova Reports ALS Trial Completion, Eyes 2026 Topline Results

MediciNova Inc. concluded its double-blind phase of the COMBAT-ALS Phase 2b/3 trial, with 234 participants across U.S. and Canadian sites, aiming for FDA/EMA regulatory pathways for MN-166 (ibudilast).

Sophie Laurent · 26 Sept 2026
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets